Good Call Media Co-owner, Fiona Molloy used her interviewing, editing and graphics skills to support our client, VolitionRX, quoted on the New York Stock Exchange, to prepare a webinar highlighting the company’s developing a programme of early detection with their Nu.Q® NETs tool.
Globally, sepsis is estimated to be contracted by about 50 million people, leading to more than 11 million deaths (c 25% mortality rate) each year. It accounts for 42% of global deaths of children under the age of five.
The condition can spread rapidly and cause multiple organ failure. Survivors can suffer life-altering consequences, with 50% left with the pathological condition of long-term sequelae.
See the Linked In posting below to take a look at how the webinar turned out:
Volition is undertaking studies to test its groundbreaking CE-marked technology as a diagnostic aid for sepsis and to monitor disease progression and treatment response.
To find out more about sepsis and Volition’s exciting work in this field, read Edison’s thematic report and watch this short video featuring Dr Andrew Retter, a consultant in intensive care specialising in sepsis. Let’s stop the rot.
To understand more about the company, take a look at Edison’s published content.